Welcome to our dedicated page for Oncocyte Corporation news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation stock.
Oncocyte Corporation (OCX) is a pioneering precision diagnostics company dedicated to the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics aimed at facilitating clinical decision-making in the early detection of cancer. The company focuses on molecular tests that address high unmet needs in the diagnosis of lung, breast, and bladder cancers, conditions where current diagnostic standards are often ambiguous, costly, and invasive. Oncocyte's tests are developed based on a proprietary set of biomarkers, designed to differentiate between benign and malignant nodules or masses.
Oncocyte’s flagship products include:
- DetermaIO™: A gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.
- DetermaCNI™: A blood-based monitoring tool for therapeutic efficacy in cancer patients.
- VitaGraft™: A blood-based solid organ transplantation monitoring test.
- GraftAssure™: A research-use-only monitoring test for solid organ transplantation.
The company has made significant strides in expanding its diagnostic capabilities and achieving key regulatory and commercial milestones. In 2023, Oncocyte secured reimbursement for VitaGraft™ Kidney, manufactured the initial lots of GraftAssure RUO, and entered a strategic partnership with Bio-Rad Laboratories to commercialize GraftAssure and develop VitaGraft Kidney IVD. This partnership, along with a successful $15.8 million private placement offering, positions Oncocyte well to meet its critical commercial and regulatory goals.
Oncocyte continues to be supported by strong core investors and aims to provide clarity and confidence to physicians and their patients through its groundbreaking diagnostic tests. For more information, visit www.oncocyte.com.
Oncocyte Corporation (Nasdaq: OCX) has announced peer-reviewed data supporting the effectiveness of its DetermaIO™ test in predicting responses to immunotherapy in high-risk early-stage triple-negative breast cancer (TNBC). Published in the journal Cancers, the study indicates that DetermaIO outperforms the standard PD-L1 IHC biomarker. The test's predictive ability was validated using biopsy samples from 55 patients involved in a neoadjuvant clinical trial. This research highlights DetermaIO's potential to guide treatment decisions early on, enhancing patient outcomes.
Oncocyte Corporation (OCX) announced positive results from the NeoTRIPaPDL1 clinical trial, showcasing DetermaIO as a predictive biomarker for immune therapy response in triple-negative breast cancer (TNBC). The trial enrolled 241 patients across multiple countries, demonstrating a 71% response rate for IO score positive patients receiving both immunotherapy and chemotherapy. This contrasts significantly with a 51% response rate in the chemotherapy-only group. DetermaIO's potential for pan-cancer application and its forthcoming clinical launch in Q4 2021 could tap into a $3 billion US market.
Oncocyte Corporation (Nasdaq: OCX) announced two key opinion leader (KOL) events focusing on advancements in cancer diagnostics. The first event, on September 22, will cover transplant rejection testing, featuring KOL Dr. Michael Oellerich, who will discuss unmet medical needs and Oncocyte's recent acquisition of capabilities for immunosuppressive therapy monitoring. The second event, on September 28, will focus on DetermaIO™, a gene expression test for triple-negative breast cancer. KOLs Dr. Priyanka Sharma and Dr. Giampaolo Bianchini will present data from a clinical trial evaluating DetermaIO as a biomarker for immunotherapy response.
Oncocyte Corporation (Nasdaq: OCX) has been recognized by Modern Healthcare as one of the 2021 Best Places to Work in Healthcare. The award highlights Oncocyte’s commitment to enhancing patient outcomes through its precision diagnostics and monitoring services. Ron Andrews, President and CEO, emphasized the company's dedication to its employees and mission during the challenges posed by the pandemic. The final ranking will be announced at the awards gala on September 16, 2021, in Chicago, showcasing the significant recognition of the company's workplace culture and its positive impact on healthcare.
Oncocyte Corporation (Nasdaq: OCX) announced the first evaluation of its DetermaIO™ assay in a randomized clinical trial for triple-negative breast cancer (TNBC). This groundbreaking study will be presented at the European Society for Medical Oncology (ESMO) Congress from September 16-21, 2021. The late-breaking oral presentation, titled Predictive value of gene-expression profiles in the Neo TRIPaPDL1 trial, will occur on September 20 at 1:30 PM EST. DetermaIO aims to predict patient responses to immuno-oncology therapies, enhancing treatment decision-making.
Oncocyte Corporation (Nasdaq: OCX) announced participation in the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference on September 14, 2021. Management will engage in one-on-one and group investor meetings aimed at presenting the company's precision diagnostics and monitoring capabilities for cancer. Oncocyte focuses on improving patient outcomes through proprietary tests like DetermaRx™ and DetermaIO™, which aid in early detection and treatment decisions in oncology. Interested investors can contact Lake Street Capital Markets for meeting arrangements.
Oncocyte Corporation (Nasdaq: OCX) has announced the launch of the Predictive Assay for Decision Making in Adjuvant Therapy (PADMA) Registry aimed at enrolling over 1,000 patients with early-stage lung cancer across 25 hospitals in the U.S. The registry seeks to collect data on the impact of biomarker adoption and precision medicine using their DetermaRx™ test, improving treatment decisions for patients post-surgery. The PADMA Registry reflects Oncocyte's commitment to enhancing patient outcomes through precise diagnostics in cancer treatment.
Oncocyte Corporation (Nasdaq: OCX) reported a 23% rise in sample volume for DetermaRx in Q2 2021. Financial results showed revenues of $2.03 million, exceeding estimates, largely due to DetermaRx's growth. The company plans to launch three new products in Q4, including DetermaIO, which demonstrates potential as a predictive biomarker for immunotherapy. The acquisition of Chronix enables entry into blood-based monitoring markets. However, Q2 operational losses widened to $13.6 million, with a net loss of $10.5 million, or ($0.12) per share.
Oncocyte Corporation (Nasdaq: OCX) announced participation in two key investor conferences. The UBS Genomics 2.0 & MedTech Innovations Summit will take place on August 12, 2021, at Montage Laguna Beach, featuring 1x1 and group meetings. Following this, the 6th Annual Needham Virtual Med Tech & Diagnostics Conference is scheduled for August 17, 2021, also with 1x1 and group formats. Oncocyte aims to enhance cancer diagnosis and treatment through its precision diagnostics and proprietary tests, including DetermaRx and DetermaIO, which are designed to improve patient outcomes.
Oncocyte Corporation (Nasdaq: OCX) announced it will release its financial results for Q2 2021 after market close on August 10, 2021. The company will host a conference call at 4:30 PM ET to discuss the results and recent developments. Oncocyte focuses on precision diagnostics for cancer, aiming to enhance patient outcomes through its proprietary tests like DetermaRx and DetermaIO. The company emphasizes its commitment to improving cancer care and accelerating diagnoses. Forward-looking statements highlight risks, including COVID-19 impacts and uncertainties in clinical development.
FAQ
What is the current stock price of Oncocyte Corporation (OCX)?
What is the market cap of Oncocyte Corporation (OCX)?
What does Oncocyte Corporation specialize in?
What types of cancer does Oncocyte's diagnostics target?
What are some of Oncocyte's key products?
How does Oncocyte's DetermaIO™ test work?
What recent achievements has Oncocyte made?
Who are some of Oncocyte's partners?
What is the purpose of Oncocyte's VitaGraft™ test?
What is GraftAssure™ used for?
How does Oncocyte support its operations financially?
Where can I find more information about Oncocyte Corporation?
